Uncategorized

We have the following takeaways on trade and tariffs regarding President Trump’s interview on CNBC this morning. While Trump mentioned that he would raise tariffs on India over the next 24 hours since India continues…

Medicare’s final FY26 payment regulations for hospices [CHE, AMED, ADUS, PNTG, BTSG, Gentiva, Compassus, Elara], inpatient rehab facilities (IRFs) [EHC, SEM], and inpatient psych facilities (IPFs) [UHS, ACHC] aligned with expectations for: 1) slightly higher aggregate spending…

Medicare’s final FY26 payment regulations for inpatient hospitals [HCA, THC, CYH, ARDT, UHS, MPW, municipal bond-backed facilities], long-term care hospitals (LTCHs) [SEM, Kindred], and skilled nursing facilities (SNFs) [ENSG, PACS, Providence] with implications for their post-acute…

With the August 1 tariff deadline tomorrow, we have the following takeaways from our trade and tariff conference call that we held yesterday morning with Derek Scissors. A transcript is available upon request. Takeaways Derek…

This morning’s Senate Appropriations Committee’s markup of the FY26 Labor / HHS funding bill, which includes a $400M increase (+0.8% YoY) for NIH, should serve as an interim clearing event for life science tools (LST)…

Against the backdrop of positive Q2 earnings, upward full-year guidance, and voiced confidence in the ability to manage the medical cost and utilization trends throughout 2H and into next year, we think the recently refiled…

We wanted to highlight our expectations for defense spending in FY26 and the upcoming legislative schedule for the defense sector.  Bottom line: we still believe that a continuing resolution (CR) funding defense at FY25 levels…

Today’s CMS release regarding its CY26 Medicare Part D program gives  the impression the agency is focusing on stability in its drug benefit program with the goal to ensure 1) enrollees – especially those in…

With the House out of session until September 2 and the Senate scheduled to leave for its August recess at the end of this week, trade seems likely to continue to dominate the headlines as…

We view CMS’s clinical laboratory advisory panel today as an incremental positive for Guardant Health (GH), despite what appears to be a lack of endorsement for the company’s request that payments for Reveal (0569U: $1,644)…